Fortune 100 companies adopt Adobe AI tools at 99% rate
HENDERSON, Nev. - VolitionRx Limited (NYSE AMERICAN:VNRX), a $65.74 million market cap diagnostics company showing 35.1% revenue growth over the last twelve months, announced Tuesday it has signed a Research License and Exclusive Commercial Option Rights Agreement with Werfen’s Immunoassay Technology Center for Antiphospholipid Syndrome (APS) testing. According to InvestingPro data, the company faces significant financial challenges with an overall WEAK financial health score.
Under the agreement, Werfen will gain access to components of Volition’s proprietary Nu.Q H3.1 NETs assay to investigate its clinical utility in managing APS patients. Werfen also secured an option to negotiate terms for potential commercial launch under an exclusive license. This development comes as InvestingPro analysis shows VolitionRx is quickly burning through cash, with current short-term obligations exceeding liquid assets.
Werfen has already transferred the Nu.Q NETs assay to its ACL AcuStar platform, according to Marta Palicio, Werfen’s Immunoassay Technology Center Innovation R&D Director. Early results in detecting Neutrophil Extracellular Traps (NETs) levels in APS patients are described as encouraging.
APS is an autoimmune disorder affecting approximately four million people worldwide. It increases the risk of blood clots and associated complications such as stroke, heart attack, and deep vein thrombosis. The condition is also linked to recurrent miscarriages and pregnancy complications.
Current APS diagnosis requires a panel of blood tests with two positive results at least 12 weeks apart. The condition typically requires lifelong monitoring and daily anticoagulant or antiplatelet medication.
According to Remi Rabeuf, Volition’s Vice President of Corporate Alliances & Strategic Partnerships, the Nu.Q NETs test could potentially improve diagnostic information for clinical decision-making while providing a low-cost monitoring option for patients.
Werfen operates in 30 countries directly and in over 100 territories through distributors. The company reported worldwide sales of €2.2 billion in 2024.
Volition is focused on epigenetics research with operations in Belgium, the United States, and London.
This article is based on information from a company press release. While analysts have set price targets ranging from $2.00 to $5.00 per share, InvestingPro subscribers can access 8 additional key insights about VNRX, including detailed financial health metrics and growth prospects. Get the complete picture with InvestingPro’s comprehensive research report, available as part of the platform’s coverage of 1,400+ US stocks.
In other recent news, VolitionRx Limited reported its Q2 2025 earnings, revealing a 15% year-over-year increase in revenue, bringing the total to over $400,000. This financial update underscores the company’s strategic focus on achieving cash neutrality by the end of 2025, as they also reported a reduction in net cash usage for operating activities. Despite these positive developments, the company’s stock experienced a decline of 2.64% in premarket trading, indicating mixed investor sentiment. These recent developments are crucial for investors to consider as they evaluate the company’s financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.